AbbVie Denies Acquisition Talks with Revolution Medicines, Stock Volatility Ensues
AbbVie has denied being in acquisition talks with Revolution Medicines after a Wall Street Journal report suggested otherwise. This denial caused Revolution Medicines' stock to drop sharply after an initial surge. Additionally, AbbVie reduced its 2025 profit forecast, raising concerns about its growth strategy.
Insights:
AbbVie Inc. has publicly denied being in advanced acquisition discussions with Revolution Medicines Inc. , following a report by the Wall Street Journal that suggested such talks were underway. This denial swiftly altered the course of Revolution Medicines' stock, which initially surged nearly 30% before reversing to close 11.5% lower in extended trading. AbbVie's own stock experienced volatility, closing 4% higher before the denial and falling 1% afterward.
The Wall Street Journal's report, which speculated that Revolution Medicines could be valued at over $20 billion with a typical acquisition premium, initially fueled investor optimism. However, AbbVie's subsequent statement to Reuters, denying any such discussions, swiftly curtailed this enthusiasm, illustrating the sensitivity of market reactions to merger and acquisition news.
